MinalAtulBarveMD(She/Her)

[Pronunciation: mee-nul, bar-vay ]

Oncology • Dallas, TX

Physician

Join to view full profile

Dr. Barve is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Barve's full profile

Already have an account?

Office
8196 Walnut Hill Ln
Ste 100
Dallas, TX 75231
Phone+1 214-739-4175

Fax+1 214-987-4161
Is this information wrong?

Education & Training

Baylor University Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2003
Texas Health Resources (Dallas)Residency, Internal Medicine, 1996 - 1999
Dr P Deshmukh Mem Medicine Coll, Amravati UniversityClass of 1993

Certifications & Licensure

TX State Medical License 2000 - 2026
CO State Medical License 1999 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Salvage Ovarian FANG™ Vaccine + Carboplatinum Start of enrollment: 2013 Jun 01
Completed
Phase 2
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Start of enrollment: 2016 Feb 10
Completed
Phase 2
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers Start of enrollment: 2016 Jun 03
Completed
Phase 2
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies Start of enrollment: 2019 May 17
Recruiting
Phase 1
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Start of enrollment: 2021 Aug 03
Active, not recruiting
Phase 1
Roles: Contact
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Start of enrollment: 2022 May 31
Recruiting
Phase 1
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas Start of enrollment: 2022 Mar 28
Recruiting
Phase 1
IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors Start of enrollment: 2022 Jun 20
Recruiting
Phase 1
TH1902 in Patients With Advanced Solid Tumors Start of enrollment: 2021 Mar 04
Recruiting
Phase 1
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Start of enrollment: 2020 Sep 23
Recruiting
Phase 1
Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors Start of enrollment: 2021 Aug 18
Recruiting
Phase 1
A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) Start of enrollment: 2021 Jun 22
Recruiting
Phase 1
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Start of enrollment: 2021 Jan 18
Recruiting
Phase 2
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Start of enrollment: 2023 Dec 28
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
Rona Yaeger, Nataliya V Uboha, Meredith S Pelster, Tanios S Bekaii-Saab, Minal Barve, Joel Saltzman, Joshua K Sabari, Julio A Peguero, Andrew Scott Paulson, Pasi A Jän...> ;Cancer Discovery. 2024 Apr 8
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Conley, A. P., Anthony P Conley, Christina L Roland, Alberto Bessudo, Brian R Gastman, Victoria M Villaflor, Christopher Larson, Tony R Reid, Scott Caroen, Bryan Orons...> ;Cancer Gene Therapy. 2024 Apr 1
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Noelia Martinez Jañez, Jose Trigo, Alastair Greystoke, R Donald Harvey, Anthony J Olszans...> ;Cancer Medicine. 2024 Mar 1
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Gerald Falchook, Amita Patnaik, Debra L Richardson, R Donald Harvey, Manish R Sharma, Navid Hafez, Erika Hamilton, Sarina A Piha-Paul, Minal Barve, Trisha Wise-Draper,...> ;Clinical Therapeutics. 2024 Mar 1
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
David Pook, Daniel M Geynisman, Joan Carles, Filippo de Braud, Anthony M Joshua, José Luis Pérez-Gracia, Casilda Llácer Pérez, Sang Joon Shin, Bruno Fang, Minal Barve,...> ;Clinical Cancer Research. 2023 Sep 1
1 citations
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.
Sibel Blau, Julio Antonio Peguero, Halle C F Moore, Ian Churchill Anderson, Minal A Barve, Mathew Amprayil Cherian, Ahmed Elkhanany, Ciara Catherine O'Sullivan, Alvaro...> ;JCO Clinical Cancer Informatics. 2023 Jun 1
20 citations
Adagrasib in Advanced Solid Tumors Harboring aMutation.
Tanios S Bekaii-Saab, Rona Yaeger, Alexander I Spira, Meredith S Pelster, Joshua K Sabari, Navid Hafez, Minal Barve, Karen Velastegui, Xiaohong Yan, Aditya Shetty, Hir...> ;Journal of Clinical Oncology. 2023 Sep 1
13 citations
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Johanna Bendell, Patricia LoRusso, Michael Overman, Anne M Noonan, Dong-Wan Kim, John H Strickler, Sang-We Kim, Stephen Clarke, Thomas J George, Peter S Grimison, Mina...> ;Cancer Immunology, Immunotherapy. 2023 Jul 1
4 citations
Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
Jun Zhang, Melissa Johnson, Minal Barve, Lyudmila Bazhenova, Marybeth McCarthy, Rowena Schwartz, Elise Horvath-Walsh, Karen Velastegui, Chunlin Qian, Alexander Spira> ;The Oncologist. 2023 Apr 6
82 citations
Adagrasib with or without Cetuximab in Colorectal Cancer with MutatedG12C.
Rona Yaeger, Jared Weiss, Meredith S Pelster, Alexander I Spira, Minal Barve, Sai-Hong I Ou, Ticiana A Leal, Tanios S Bekaii-Saab, Cloud P Paweletz, Grace A Heavey, Ja...> ;The New England Journal of Medicine. 2023 Jan 5
2 citations
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 A...
John Heymach, Frans Opdam, Minal Barve, Neil Gibson, Behbood Sadrolhefazi, Josep Serra, Noboru Yamamoto> ;Clinical Lung Cancer. 2023 Mar 1
5 citations
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.
Aung Naing, Alain P Algazi, Gerald S Falchook, Benjamin C Creelan, John Powderly, Seth Rosen, Minal Barve, Niharika B Mettu, Pierre L Triozzi, John Hamm, Gongfu Zhou, ...> ;Cancer. 2023 Jan 1
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN...
Jonathon B Cohen, Nirav N Shah, Alvaro J Alencar, James N Gerson, Manish R Patel, Bita Fakhri, Wojciech Jurczak, Xuan Ni Tan, Katharine L Lewis, Timothy Fenske, Cather...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
6 citations
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Santosh Kesari, Alberto Bessudo, Brian R Gastman, Anthony P Conley, Victoria M Villaflor, Lisle M Nabell, DeLisa Madere, Emma Chacon, Christina Spencer, Li Li, Christo...> ;Future Oncology. 2022 Sep 1
90 citations
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With AdvancedSolid Tumors (KRYSTAL-1).
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, Igor I Rybkin, Joshua K Sabari, Minal A Barve, Lyudmila Bazhenova, Melissa L Johnson, Karen L Velastegui, Cornelius...> ;Journal of Clinical Oncology. 2022 Aug 10
7 citations
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, Daniel Morgensztern, Rebecca Heist, Everett Vokes, Eric Angevin, David S Hong, Igor I Rybkin, Minal Barve, Todd M ...> ;JTO Clinical and Research Reports. 2022 Jan 1
6 citations
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
Minal Barve, Phylicia Aaron, Luisa Manning, Ernest Bognar, Gladice Wallraven, Staci Horvath, Laura Stanbery, John Nemunaitis> ;Clinical Medicine Insights. Oncology. 2022 Jan 1
3 citations
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6.
Vedin Barve, Ned Adams, Laura Stanbery, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Minal A. Barve, John Nemunaitis> ;Vaccines. 2021 Oct 18
21 citations
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Ca...
D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist, Minal A. Barve, Everett E. Vokes, Jonathan W. Goldman, David S. Hong, Todd M. Bauer, John H. Strickler, Eric An...> ;Clinical Cancer Research. 2021 Aug 23
3 citations
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
Michael S. Gordon, John Nemunaitis, Minal A. Barve, Zev A. Wainberg, Erika Hamilton, Ramesh K. Ramanathan, George W. Sledge, Huibin Yue, Susan E. Morgan-Lappe, Martha ...> ;Molecular Cancer Therapeutics. 2021 Jul 26
2 citations
Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cance...
Jermaine Coward, Minal A. Barve, Ganessan Kichenadasse, Kathleen N. Moore, Paul R. Harnett, Daniel J. Berg, James Garner, Don S. Dizon> ;Cancers. 2021 Jun 26
204 citations
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Yoon Cheah, John M. Pagel, Jennifer A. Woyach, Bita Fakhri, Toby A. Eyre, Nicole Lamanna, Manish R. Patel, Alvar...> ;Lancet. 2021 Mar 6
3 citations
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol....
Jonathan Oh, Minal A. Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley, John Nemunaiti...> ;Gynecologic Oncology Reports. 2021 Mar 1
2 citations
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer
Jonathan W. Goldman, Minal A. Barve, Jyoti D. Patel, Antoinette J. Wozniak, Afshin Dowlati, Alexander Starodub, Taofeek K. Owonikoko, William Jeffery Edenfield, Scott ...> ;Clinical and Translational Science. 2021 Mar 1
61 citations
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rodney P. Rocconi, Elizabeth A. Grosen, Sharad A. Ghamande, John K. Chan, Minal A. Barve, Jonathan Oh, Devansu Tewari, Peter C. Morris, Erin E. Stevens, Justin N. Bott...> ;The Lancet. Oncology. 2020 Dec 1
Join now to see all

Press Mentions

Drug Combinations and New Approvals Delivering Optimistic Results in Oncology StocksDecember 8th, 2021
Gradalis®, Inc. Announces Dosing of First Patient in Pilot Study Combining Vigil® Engineered Autologous Tumor Cell Immunotherapy and Durvalumab in Advanced Breast CancerAugust 29th, 2016